drug development

Read more: Q&A: Alex Zhavoronkov on Cognitive Enhancement, Anti-Aging, and AI Drug Development

Article

August 28, 2024

Q&A: Alex Zhavoronkov on Cognitive Enhancement, Anti-Aging, and AI Drug Development

Interviewed by William Leonard Pickard Alex Zhavoronkov, PhD, is Founder and CEO of Insilico Medicine, a leading clinical stage biotechnology company developing next-generation artificial intelligence and robotics platforms for drug discovery, with headquarters in Cambridge, MA and facilities around the world. He has invented critical technologies for the creation of novel molecular structures, and pioneered the…
Read more: FDA Solicits Feedback on the Use of AI and Machine Learning in Drug Development

Article

June 12, 2023

FDA Solicits Feedback on the Use of AI and Machine Learning in Drug Development

The FDA has recently turned its attention to the growing use of artificial intelligence and machine learning in drug development.
Read more: Washington Psilocybin Bill Would Legalize Supported Adult Use

Article

January 5, 2022

Washington Psilocybin Bill Would Legalize Supported Adult Use

On Tuesday, Washington State legislators filed a bill that would legalize the supported adult use of psilocybin by people 21 years of age and older.
Read more: Expanding The Right to Try Unproven Treatments: A Dangerous, Deregulatory Proposal

Article

June 7, 2021

Expanding The Right to Try Unproven Treatments: A Dangerous, Deregulatory Proposal

As has been proven time and again, “gut feeling” and wishful thinking have never been shown to replace controlled clinical testing.
Read more: Excluding Pregnant People From Clinical Trials Reduces Patient Safety and Autonomy

Article

April 16, 2021

Excluding Pregnant People From Clinical Trials Reduces Patient Safety and Autonomy

The exclusion of pregnant people from clinical trials has led to inequities in health care during pregnancy.
Read more: Year in Review: Biosimilars

Article

January 26, 2021

Year in Review: Biosimilars

In November 2020, the FDA released its most recent draft guidance for industry on biosimilarity and interchangeability
Read more: Psychedelics Helped Me Reclaim My Life and Push to Change Drug Laws

Article

October 28, 2020

Psychedelics Helped Me Reclaim My Life and Push to Change Drug Laws

I am not the usual protagonist you’d imagine as an advocate for psychedelics. But I had a psychedelic experience that changed my life.
Read more: Psychedelics and America: A Digital Symposium

Article

October 27, 2020

Psychedelics and America: A Digital Symposium

This digital symposium for the Petrie-Flom Center’s Bill of Health blog explores the role psychedelics may play in America’s future.
Read more: As Cities Decriminalize Psychedelics, Law Enforcement Should Step Back

Article

August 5, 2020

As Cities Decriminalize Psychedelics, Law Enforcement Should Step Back

Psychedelics may fill the growing need for innovative psychiatric drugs. Some cities, dissatisfied with the U.S. war on drugs, are decriminalizing them.

drug development

Q&A: Alex Zhavoronkov on Cognitive Enhancement, Anti-Aging, and AI Drug Development

FDA Solicits Feedback on the Use of AI and Machine Learning in Drug Development

Washington Psilocybin Bill Would Legalize Supported Adult Use

Expanding The Right to Try Unproven Treatments: A Dangerous, Deregulatory Proposal

Excluding Pregnant People From Clinical Trials Reduces Patient Safety and Autonomy

Year in Review: Biosimilars

Psychedelics Helped Me Reclaim My Life and Push to Change Drug Laws

Psychedelics and America: A Digital Symposium

As Cities Decriminalize Psychedelics, Law Enforcement Should Step Back